Please login to the form below

escitalopram

This page shows the latest escitalopram news and features for those working in and with pharma, biotech and healthcare.

protection for Abilify and former blockbuster antidepressant Lexapro/Celexa (escitalopram).

Surging sales of Lundbeck's CNS drugs assist recovery

Since its former blockbuster Cipralex (escitalopram) started to succumb to generic competition, Lundbeck has looked to two newer antidepressants - Brintellix/Trintellix (vortioxetine) and Rexulti (brexpiprazole) - to step in and fill the
Lundbeck to cut 1,000 jobs in major restructure

sales from drugs such as depression treatment Cipralex (escitalopram).
US filing aims to elevate Brintellix above its competition

Brintellix has been on the market in the US since 2013 and has been positioned as a successor to its older antidepressant Cipralex (escitalopram), which was selling around $2bn a year
Lundbeck and Otsuka's Rexulti set for August launch in US

which it hopes will restore growth after the loss of patent protection on US blockbuster antidepressant Lexapro/Celexa (escitalopram).
Schultz takes Lundbeck helm after leaving Novo Nordisk

to continued generic competition to Alzheimer's therapy Ebixa (memantine) and antidepressant Cipralex (escitalopram).

More from news
Approximately 2 fully matching, plus 38 partially matching documents found.

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

Add my company

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Report: Achieving launch excellence in the challenging healthcare markets of today: Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham: Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone: Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...